International Journal of Cell Science and Biotechnology
E-ISSN 2320-7574

Available at Available at https://ijcsb.evegenis.org/

Original Review Article

mRNA Vaccine Platforms and the COVID-19 Pandemic: Mechanisms, Immunogenicity, and Future Prospects

Klaus H. Hoffmann[1]*, Sarah J. Pemberton[2] and Anke M. Brünner[1]

[1]Institute of Vaccinology and RNA Therapeutics, Johannes Gutenberg University Mainz, 55131 Mainz, Germany
[2]Jenner Institute, University of Oxford, Oxford OX3 7DQ, United Kingdom

Received 10 Apr 2021, Accepted 20 May 2021, Available online 25 May 2021, **Vol.10 (2021)**

Abstract

The emergence of COVID-19 caused by SARS-CoV-2 in late 2019 precipitated an unprecedented global public health crisis, galvanising the scientific community to develop effective vaccines at record speed. Among the transformative outcomes of this pandemic response was the emergency use authorisation of the first-ever messenger RNA (mRNA)-based vaccines in humans—BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)—within twelve months of viral sequence disclosure. BNT162b2 was co-developed by BioNTech, headquartered in Mainz, Germany, in partnership with Pfizer, making this a landmark achievement for European vaccinology. This review comprehensively examines the molecular biology of mRNA vaccine technology, including structural components, codon optimisation strategies, nucleoside modification approaches pioneered by Karikó and Weissman, and lipid nanoparticle delivery systems. We review the immunological mechanisms underlying mRNA vaccine-induced humoral and cellular immunity, analyse efficacy and safety data from pivotal Phase III trials, and discuss the limitations of the platform including cold chain requirements and durability of immune responses. Finally, we discuss emerging mRNA vaccine applications beyond COVID-19, positioning mRNA technology as a cornerstone of 21st-century vaccinology.

Keywords: *mRNA Vaccines, COVID-19, SARS-CoV-2, Lipid Nanoparticles, BNT162b2; mRNA-1273, Nucleoside Modification, Immunogenicity, BioNTech, Vvaccinology*

1. Introduction

emergency by the World Health Organization in March 2020. The pandemic created urgent demand for effective preventive vaccines. Traditional vaccine development timelines typically span 10–15 years; however, the COVID-19 pandemic compressed this timeline to under twelve months through the convergence of prior coronavirus research, platform technology readiness, parallel development, regulatory innovation, and extraordinary global investment (Dolgin, 2021). Critically, BioNTech—a German biopharmaceutical company founded in Mainz and led by Dr. Uğur Şahin and Dr. Özlem Türeci—and Oxford's Jenner Institute were at the scientific frontier of this development, representing Europe's central contribution to the mRNA vaccine revolution.

Among the diverse vaccine platforms deployed against SARS-CoV-2, the mRNA-based vaccines achieved over 90% efficacy against symptomatic disease in pivotal Phase III trials (Polack et al., 2020; Baden et al., 2021). This represented not only a landmark achievement in pandemic response but also the first regulatory approval of any mRNA therapeutic in humans, validating decades of foundational research into mRNA stability, delivery, and immunogenicity.

The conceptual basis of mRNA vaccines is elegant: synthetic mRNA encoding a target antigen is delivered into human cells, which then transiently produce the encoded protein, triggering adaptive immune responses without the introduction of live pathogen or DNA. However, translating this concept into safe, effective clinical products required overcoming substantial obstacles, including mRNA instability in biological fluids, inefficient cellular uptake, innate immune activation by exogenous RNA, and cold chain logistics (Pardi et al., 2018).

2. Historical Development of mRNA Vaccine Technology

2.1 Early Discoveries

The possibility of using mRNA as a therapeutic agent was first demonstrated by Malone et al. (1989). However, early studies were hampered by mRNA instability and the strong innate immune activation

*Corresponding author: **Klaus H. Hoffmann**
DOI: https://doi.org/10.14741/ijcsb/v.10.1.2

triggered by exogenous RNA through pattern recognition receptors. The seminal work of Karikó and Weissman (2005) fundamentally transformed the field by demonstrating that pseudouridine substitution for uridine in synthetic mRNA dramatically reduced innate immune activation while enhancing translational efficiency—a discovery honoured with the 2023 Nobel Prize in Physiology or Medicine. European researchers at Mainz, Tübingen, and Cambridge contributed substantially to early-stage lipid nanoparticle optimisation that made clinical mRNA delivery feasible.

2.2 Lipid Nanoparticle Development

The development of ionisable lipid nanoparticles—neutral at physiological pH but positively charged at low endosomal pH—dramatically improved safety and endosomal escape efficiency of mRNA delivery (Semple et al., 2010). The ionisable lipids ALC-0315 (BNT162b2, developed partly through European academic-industry collaboration) and SM-102 (mRNA-1273) represent the culmination of decades of lipid engineering effort.



Figure 1: Timeline of Key Milestones in mRNA Vaccine Development (1989–2021). Notable European contributions include BioNTech (Mainz, Germany) development of BNT162b2 and Oxford Jenner Institute's parallel RNA vaccine programme. LNP = lipid nanoparticle; EUA = Emergency Use Authorisation.

3. Molecular Architecture of COVID-19 mRNA Vaccines

3.1 Antigen Design and mRNA Optimisation

Both BNT162b2 and mRNA-1273 encode a prefusion-stabilised full-length spike (S) protein of SARS-CoV-2 with proline substitutions at K986P and V987P. The synthetic mRNA contains: a 5′ Cap1 structure; optimised 5′ and 3′ UTRs; a poly(A) tail of approximately 100 adenosine residues; codon-optimised S protein coding sequence; and substitution of all uridines with N1-methylpseudouridine (m1Ψ) (Corbett et al., 2020). BioNTech's proprietary RNAX platform, developed in Mainz, incorporates additional stabilisation elements that contributed to the superior thermostability achieved in later formulations.

Table 1: Comparison of Key Features of BNT162b2 and mRNA-1273 COVID-19 mRNA Vaccines

Feature	BNT162b2 (Comirnaty)	mRNA-1273 (Spikevax)
Developer	BioNTech (Mainz, Germany) / Pfizer	Moderna / NIAID, USA
mRNA dose per injection	30 µg	100 µg
Nucleoside modification	N1-methylpseudouridine	N1-methylpseudouridine
Ionisable lipid	ALC-0315	SM-102
Antigen encoded	Full-length S protein (K986P/V987P)	Full-length S protein (K986P/V987P)
Dosing schedule	2 doses, 21 days apart	2 doses, 28 days apart
Storage temperature	−80 to −60°C (original)	−50 to −15°C
Phase III efficacy	95.0% (95% CI: 90.3–97.6%)	94.1% (95% CI: 89.3–96.8%)
EUA date	11 December 2020	18 December 2020

EUA = Emergency Use Authorisation; NIAID = National Institute of Allergy and Infectious Diseases.

4. Immunological Mechanisms

4.1 Innate and Adaptive Immune Responses

Following intramuscular injection, LNP-mRNA formulations are taken up by local dendritic cells and macrophages at the injection site and in draining lymph nodes.



Figure 2: Schematic of mRNA Vaccine Mechanism of Action. LNP-delivered mRNA is translated by ribosomes into spike protein, processed through MHC pathways, and presented to T and B lymphocytes, generating humoral and cellular adaptive immunity.

5. Clinical Efficacy and Safety

Endosomal acidification triggers ionisable lipid protonation, facilitating mRNA cytoplasmic release and ribosomal translation of spike protein. MHC-I and MHC-II pathways present spike epitopes to CD8+ and CD4+ T cells respectively. mRNA COVID-19 vaccines elicit robust neutralising antibody titres substantially exceeding those observed following natural infection (Doria-Rose et al., 2021), alongside durable CD4+ and CD8+ T cell responses.

The pivotal Phase III COVE trial of BNT162b2 (n = 43,548) demonstrated 95.0% efficacy against symptomatic COVID-19 with near-complete protection against severe disease (Polack et al., 2020). mRNA-1273 similarly demonstrated 94.1% efficacy (Baden et al., 2021). Both vaccines demonstrated acceptable safety profiles with predominantly transient reactogenicity. Rare adverse events included anaphylaxis (2–5 per million doses) and myocarditis/pericarditis in young males (1–10 per 100,000 second doses), substantially outweighed by protective benefits.

Table 2: Phase III Efficacy and Solicited Adverse Events — BNT162b2 vs. mRNA-1273

Parameter	BNT162b2	mRNA-1273
Total participants	43,548	30,420
Vaccine efficacy (symptomatic)	95.0%	94.1%
Efficacy vs. severe disease	~100%	100%
Injection site pain	83.1%	91.6%
Fatigue (any grade)	62.9%	68.5%
Fever ≥38°C (Dose 2)	14.2%	15.8%
Severe adverse events	0.6%	0.6%

Data from Polack et al. (2020) and Baden et al. (2021). Reactogenicity predominantly transient (1–3 days).

6. Future Directions

Future directions include thermostable mRNA formulations employing lyophilisation; self-amplifying RNA platforms requiring dramatically lower doses; multi-valent or pan-coronavirus mRNA vaccines; and personalised neoantigen mRNA vaccines for oncology—a field in which both BioNTech and CureVac (Tübingen, Germany) are advanced clinical programmes. European regulatory frameworks through the EMA are evolving to accommodate novel mRNA therapeutics with adaptive pathways established through the COVID-19 experience.

7. Conclusions

The development and deployment of mRNA COVID-19 vaccines within twelve months of viral sequence disclosure represents one of the most remarkable achievements in the history of medicine and biotechnology. Built on three decades of foundational science and validated in part through European academic-industry collaboration centred in Mainz and Oxford, these vaccines demonstrated that mRNA technology could be translated rapidly into safe, highly effective clinical products. The full transformative potential of this technology for human health is only beginning to be realised.

References

Baden, L. R., El Sahly, H. M., Essink, B., et al. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine, 384(5), 403–416.

Corbett, K. S., Flynn, B., Foulds, K. E., et al. (2020). Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. New England Journal of Medicine, 383(16), 1544–1555.

Dolgin, E. (2021). The tangled history of mRNA vaccines. Nature, 597(7876), 318–324.

Doria-Rose, N., Suthar, M. S., Makowski, M., et al. (2021). Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. New England Journal of Medicine, 384(23), 2259–2261.

Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification. Immunity, 23(2), 165–175.

Malone, R. W., Felgner, P. L., & Verma, I. M. (1989). Cationic liposome-mediated RNA transfection. Proceedings of the National Academy of Sciences, 86(16), 6077–6081.

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261–279.

Polack, F. P., Thomas, S. J., Kitchin, N., et al. (2020). Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. New England Journal of Medicine, 383(27), 2603–2615.

Semple, S. C., Akinc, A., Chen, J., et al. (2010). Rational design of cationic lipids for siRNA delivery. Nature Biotechnology, 28(2), 172–176.